The company will address needs in personal nutrition, aquaculture, and biofuel with a single crop.
Aurora Algae Inc. (Hayward, CA), a relatively new algae supplier with production in Western Australia, has launched its A2 natural products portfolio for the biofuel, aquaculture, and health food industries.
The A2 line includes A2 Protein, a complete vegetarian protein source providing every essential amino acid, and A2 EPA Pure, a vegetarian source of the omega-3 eicosapentaenoic acid (EPA).
Aura Algae says its crude algal oil boasts a concentration of 65% EPA, compared to the industry standard 18% for crude fish oil.
“With A2 EPA Pure, we’ll make a significant contribution to the nutraceutical and pharmaceutical industries, providing a new sustainable, continuous source of EPA in the highest natural concentration available to date,” said Leslie van der Meulen, vice president of business development for Aurora Algae.
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
Krill oil supplementation raises Omega-3 Index of Lupus patients in recent study
July 16th 2024The study was conducted at 20 research centers in the United States by Aker BioMarine and the Lupus Clinical Investigators Network with oversight by Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.